AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Oncolytics Biotech Reports Promising Pelareorep Data in Cancer Treatment
ByAinvest
Tuesday, Jul 8, 2025 4:39 pm ET1min read
Oncolytics Biotech has announced promising clinical data for pelareorep, demonstrating strong survival benefits in metastatic pancreatic ductal adenocarcinoma and HR+/HER2- metastatic breast cancer. The data shows a two-year survival rate of 21.9% in pancreatic cancer and a median overall survival benefit of over 10 months in breast cancer. The company plans to leverage its fast-track status to expedite regulatory pathways for pelareorep's advancement.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has announced promising clinical data for its immunotherapy treatment, pelareorep, demonstrating strong survival benefits in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer patients. The company reported a two-year survival rate of 21.9% in mPDAC patients receiving pelareorep, compared to a 9.2% historical benchmark. Additionally, the company cited a 62% objective response rate when pelareorep was combined with chemotherapy and a checkpoint inhibitor. In HR+/HER2- metastatic breast cancer studies, pelareorep showed median overall survival benefits exceeding 10 months compared to standard chemotherapy treatments. The BRACELET-1 study showed median progression-free survival of 12.1 months for patients receiving pelareorep with paclitaxel versus 6.4 months for those receiving paclitaxel alone [1].Oncolytics Biotech plans to leverage its fast-track status to expedite regulatory pathways for pelareorep's advancement. The company aims to take pelareorep directly into registration-enabling trials, utilizing its fast-track status to find the most efficient regulatory path forward this summer [1].
The clinical-stage biotechnology company's stock is currently trading near its Fair Value, reflecting market confidence in its clinical developments [2].
References:
[1] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-highlights-transformative-pelareorep-survival-data-in-multiple-tumors-and-commitment-to-registration-enabling-studies/
[2] https://www.investing.com/news/company-news/oncolytics-biotech-reports-improved-survival-rates-in-cancer-studies-93CH-4126610
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet